<?xml version="1.0" encoding="UTF-8"?>
<p>Lopinavir and ritonavir (LPV/r) (
 <xref ref-type="fig" rid="jcm-09-02084-f008">Figure 8</xref>, see brief description in 
 <xref rid="jcm-09-02084-t002" ref-type="table">Table 2</xref>) are two antiviral drugs acting as viral protease inhibitors, currently used against HIV (human immunodeficiency virus) infection [
 <xref rid="B108-jcm-09-02084" ref-type="bibr">108</xref>]. Structurally, the two compounds are 1,6-diphenyl-4-hydroxy-2,5-diaminohexane derivatives whose amino groups contain side chains with various substituted cyclic moieties such as phenoxy/3,5-diazinan (Lopinavir) or 1,3-thiazole (
 <xref ref-type="fig" rid="jcm-09-02084-f008">Figure 8</xref>). Given their molecular structure, both compounds share similar pharmacokinetic profiles based on their calculated ADME profile (
 <xref ref-type="fig" rid="jcm-09-02084-f008">Figure 8</xref> and 
 <xref ref-type="fig" rid="jcm-09-02084-f009">Figure 9</xref>). Previous studies showed that the combination of the two compounds had a beneficial effect against CoVs infections such as SARS-CoV, which triggered the investigation of their potential antiviral effect against SARS-CoV-2 as well [
 <xref rid="B109-jcm-09-02084" ref-type="bibr">109</xref>].
</p>
